Samsung Biologics Launches CHF 1.46 Billion Tender Offer for PolyPeptide
Samsung Biologics has published its formal offer prospectus to acquire PolyPeptide, deepening its push into peptide manufacturing as CDMOs race to expand capacity for GLP-1 and other peptide-based drugs.
Samsung Biologics, a contract development and manufacturing organization (CDMO), through its direct Swiss subsidiary, Samsung Peptide, has published the tender offer prospectus for all publicly held registered shares of PolyPeptide.
PolyPeptide shareholders will receive CHF 44.31 net in cash for each PolyPeptide share, representing an implied aggregate equity value of approximately CHF 1.46 billion. The offer price represents a 40% premium compared with the unaffected price of PolyPeptide’s shares on the SIX Swiss Exchange (“SIX”) as of April 10, 2026, which was the last trading day prior to the publication of the first media speculation regarding a potential acquisition of PolyPeptide. The offer price represents a premium of 11.6% compared with the volume-weighted average share price over the last 60 trading days prior to the pre-announcement on July 20, 2026.
The Board of Directors of PolyPeptide, acting through its independent and non-conflicted members, unanimously recommends that PolyPeptide's shareholders accept the offer. The recommendation is further supported by an independent fairness opinion from IFBC AG.
Draupnir Holding, PolyPeptide's largest individual shareholder, who holds approximately 55.65% of the total PolyPeptide shares outstanding, has undertaken to tender all of its shares into the offer.
The main offer period commences on Sept. 15, 2026 and is expected to end on Oct. 12, 2026. The offer is subject to a minimum acceptance threshold of 66⅔% on a fully diluted share count basis (excluding treasury shares), applicable regulatory approvals, and other customary conditions described in the Offer Prospectus.
Following the settlement of the offer, Samsung Peptide intends to pursue a squeeze-out of any remaining minority shareholders and to delist PolyPeptide’s shares from the SIX.
